Cognoa Canvas Dx
Cognoa
FDA-authorized AI for autism spectrum disorder diagnosis in children
Decision Summary
Fits
- Larger organizations
- Psychiatric NP/PA
Cost Notes
- Per-provider pricing model
- No free trial available
About Cognoa Canvas Dx
Canvas Dx is the first FDA-authorized AI-based diagnostic aid for autism spectrum disorder, helping clinicians diagnose ASD in children ages 18 months to 6 years with high accuracy.
Best For
- • Pediatricians wanting to screen for autism in-office
- • Health systems reducing autism diagnosis wait times
- • Developmental clinics increasing diagnostic capacity
- • Primary care expanding autism assessment access
- • Early intervention programs identifying children sooner
- • Practices in underserved areas lacking specialist access
Not Ideal For
- • Children outside the 18 month - 6 year age range
- • Standalone diagnosis without clinical oversight (requires provider)
- • Non-clinical direct-to-consumer use
- • Adult autism assessment
Integrations
EpicCernerMobile app
Pricing
Pricing not available
Compliance & Security
HIPAAYes
BAA AvailableYes
SOC 2Yes
HITRUSTUnknown
Always verify compliance directly with the vendor.
Target Audience
Roles
Psychiatric NP/PA
Related Tools
Floreo
VR social skills and communication therapy for autism and neurodivergent individuals
Akili Interactive (EndeavorRx, EndeavorOTC)
First FDA-cleared video game digital therapeutic for ADHD in children and adults.
Big Health (Sleepio, Daylight)
First FDA-cleared DTx for anxiety (DaylightRx) and insomnia (SleepioRx) with Medicare coverage.
Blueprint
Free EHR with AI assistant and measurement-based care for therapists.
Looking for alternatives?
Compare Cognoa Canvas Dx with similar tools and find the best fit for your practice.